Search

Charles River Laboratories International Inc

Закрыт

СекторЗдравоохранение

294.14 6.09

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

276.19

Макс.

289.3

Ключевые показатели

By Trading Economics

Доход

14M

-760K

Продажи

8.2M

1B

Прибыль на акцию

3.02

Рентабельность продаж

-0.076

Сотрудники

18,300

EBITDA

87M

151M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+1.74% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.1B

13B

Предыдущая цена открытия

288.05

Предыдущая цена закрытия

294.14

Новостные настроения

By Acuity

50%

50%

128 / 339 Рейтинг в Healthcare

Charles River Laboratories International Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 сент. 2026 г., 23:36 UTC

Social Media

Charles River Laboratories International Inc is trading lower in after-market hours, near the low end of its one-month range ahead of its investor day.

22 сент. 2026 г., 23:15 UTC

Charles River Laboratories International Inc saw a modest increase in after-market trading, maintaining a strong position above its 20-day moving average.

18 сент. 2026 г., 20:07 UTC

News

Charles River Laboratories International Inc shares fell sharply, settling near the lower end of their one-month range and below the 20-day moving average.

17 сент. 2026 г., 20:07 UTC

News

Charles River Laboratories shares are advancing as Argus lowers its price target to $330, citing strong earnings growth and improved market conditions.

16 сент. 2026 г., 19:26 UTC

Macro Event

Charles River Laboratories is trading roughly flat, showing little change since Tuesday, amid broader market volatility following the Federal Reserve's recent interest rate hike.

15 сент. 2026 г., 20:07 UTC

Charles River Laboratories shares are roughly flat amid broader market declines. The NY Empire State Manufacturing Index fell sharply, raising economic contraction concerns.

14 сент. 2026 г., 20:07 UTC

Charles River Laboratories shares are lower amid broader market concerns about rising crude oil prices and inflation, despite earlier session volatility.

10 сент. 2026 г., 19:46 UTC

Charles River Laboratories is declining for a fourth consecutive session, influenced by macroeconomic factors and trading below its 20-day moving average.

9 сент. 2026 г., 23:36 UTC

Charles River Laboratories shares are trading slightly higher in after-market hours, despite remaining below their 20-day moving average after recent declines.

8 сент. 2026 г., 20:07 UTC

Charles River Laboratories International Inc shares declined during Tuesday's session, remaining near the lower end of their one-month trading range.

4 сент. 2026 г., 19:16 UTC

Shares of Charles River Laboratories International Inc. are lower today amid notable volatility and broader market concerns about potential Federal Reserve interest rate hikes.

3 сент. 2026 г., 23:01 UTC

Charles River Laboratories is higher in after-market trading, recovering from an initial dip and nearing the upper end of its one-month trading range.

2 сент. 2026 г., 22:02 UTC

Shares of Charles River Laboratories are lower in after-market trading following a volatile session. Broader market dynamics may be influencing the asset's movement.

1 сент. 2026 г., 22:06 UTC

Charles River Laboratories shares rose after-market, continuing to show resilience despite broader market pressure from rising bond yields and inflation expectations.

31 авг. 2026 г., 20:07 UTC

Charles River Laboratories is lower today amid broader market pressures from inflation concerns and potential interest rate hikes following the Jackson Hole Economic Symposium.

28 авг. 2026 г., 23:36 UTC

Charles River Laboratories is advancing in after-market trading, continuing its upward movement since Friday's close amid broader market dynamics. No specific news was identified.

27 авг. 2026 г., 22:01 UTC

Charles River Laboratories shares are higher in after-market hours, reflecting a positive trend despite earlier session volatility. Market factors remain under close observation.

26 авг. 2026 г., 19:16 UTC

Correlated Moves

Charles River Laboratories reports first-quarter revenue of $1.03 billion, missing estimates. Shares are lower amid sector declines and ongoing inflation concerns.

25 авг. 2026 г., 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, maintaining a position near the upper end of their one-month range amid lower crude oil prices.

24 авг. 2026 г., 19:16 UTC

Correlated Moves

Charles River Laboratories is trading roughly flat amid a notable decline in Agilent Technologies. Market focus is on upcoming events, including a Federal Reserve speech.

21 авг. 2026 г., 23:01 UTC

Charles River Laboratories shares declined in after-market trading, amid broader market volatility tied to rising U.S. Treasury yields and inflation concerns.

20 авг. 2026 г., 19:41 UTC

News

Charles River Laboratories partners with Medigen to develop a multivalent enterovirus vaccine, supporting regulatory readiness and non-clinical studies. Shares are trading higher.

19 авг. 2026 г., 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, reaching a notable increase since Wednesday's close and positioning near the upper end of its one-month range.

17 авг. 2026 г., 19:26 UTC

Charles River Laboratories shares are higher today, continuing an upward trend since Friday's close. The stock remains near the top of its one-month trading range.

14 авг. 2026 г., 19:46 UTC

Charles River Laboratories shares are lower amid broader market declines following a drop in U.S. retail sales, indicating potential weakening consumer demand.

13 авг. 2026 г., 19:52 UTC

Correlated Moves

Charles River Laboratories shares are lower today amid rising jobless claims and volatility, reflecting a decline since Wednesday's close.

12 авг. 2026 г., 20:51 UTC

Charles River Laboratories is higher in after-market trading, reflecting positive momentum despite no specific news. Broader market dynamics appear to support this resilience.

11 авг. 2026 г., 19:56 UTC

Charles River Laboratories International Inc. shares are trading higher today, maintaining a position above the 20-day moving average amid routine price movements.

10 авг. 2026 г., 19:16 UTC

News

Charles River Laboratories shares rise as TD Cowen and Mizuho raise price targets to $300 and $264, respectively. The stock shows notable strength since Friday.

7 авг. 2026 г., 19:51 UTC

News

Morgan Stanley raised its price target on Charles River Laboratories to $300, maintaining an Overweight rating as shares move higher since Thursday's close.

Сравнение c конкурентами

Изменение цены

Charles River Laboratories International Inc Прогноз

Целевая цена

By TipRanks

1.74% рост

Прогноз на 12 месяцев

Средняя 290.083 USD  1.74%

Максимум 330 USD

Минимум 219 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для Charles River Laboratories International Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

13 ratings

11

Покупка

2

Удержание

0

Продажа

Настроения

By Acuity

128 / 339Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.